• 1
    Sollinger HW, for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225232.
  • 2
    Pirsh JD, Miller J, Deierhoi MH, Vicenti F, Filo R. Comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977983.
  • 3
    Neylan JF, for the US Renal Transplant Mycophenolate Mofetil Study Group. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997; 64: 12771282.
  • 4
    Neylan JF, for the FK506 Kidney Transplant Study Group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65: 515523.
  • 5
    Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161165.
  • 6
    Nashan B, Light S, Hardie IR, Lin A, Johson R, for the Daclizumab Double Therapy Study Group. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110115.
  • 7
    Meier-Kriesche H-U, Kaza H, Palekar SS et al. The effect of daclizumab in a high-risk renal transplant population. Clin Transplant 2000; 14: 509513.
  • 8
    Levey AS, Bosch JP, Breyer Lewis J et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461470.
  • 9
    Opelz G, Engelmann A. Effect of HLA matching in cyclosporine-treated Black kidney transplant recipients. Transplant Proc 1989; 21: 38813883.
  • 10
    Zhou YC, Cecka JM, Terasaki PI. Effect of race on kidney transplants. In: TerasakiPI, ed. Clinical Transplants 1990. Los Angeles: UCLA Tissue Typing Laboratory; 1990. pp 447459.
  • 11
    Vasquez EM, Benedetti E, Pollak R. Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection. Transplantation 2001; 71: 229233.
  • 12
    Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD. Possible contribution of pre-transplant immune responder status to renal allograft survival difference of black versus white recipients. Transplantation 1991; 51: 338342.
  • 13
    Butkus DE, Maydrech EF, Raju SR. Racial differences in the survival of cadaveric renal allografts: overriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992; 327: 840845.
  • 14
    Koyama H, Cecka JM, Terasaki P. Kidney transplants in blacks recipients: HLA matching and other factors affecting long-term graft survival. Transplantation 1994; 57: 10641068.
  • 15
    Scantlebury V, Gjertson D, Eliasziw M et al. Effect of HLA mismatch in African-Americans. Transplantation 1998; 65: 586588.
  • 16
    Hata Y, Ozawa M, Takemoto SK, Cecka JM. HLA matching. In: CeckaJM, TerasakiPI, eds. Clinical Transplants 1996. Los Angeles: UCLA Tissue Typing Laboratory; 1997. pp 381396.
  • 17
    Butkus DE, Dottes Al, Meydrech EF, Barber WH. Effect of poverty and other socioeconomic variables on renal allograft survival. Transplantation 2001; 72: 261266.
  • 18
    Gaston RS, Hudson SL, Ward M, Jones P, Macon R. Late renal allograft loss: noncompliance masquerading as chronic rejection. Transplant Proc 1999; 31 (4A): 21S23S.
  • 19
    Ojo AO, Port FK, Held PJ et al. Inferior outcome of two-haplotype matched renal transplants in blacks: role of early rejection. Kidney Int 1995; 48: 15921599.
  • 20
    Vasquez EM, Benedetti E, Pollack R. Late acute rejection in more prevalent among African-American renal allograft recipients and is frequently associated with allograft loss. Transplant Proc 1998; 30: 11731175.
  • 21
    Milgrom M, Gharagozloo H, Gomez C et al. Results of renal transplantation in Miami analyzed by race. Transplant Proc 1989; 21: 39343936.
  • 22
    Vincenti F, for the Tacrolimus Kidney Transplant Study Group. Tacrolimus (FK506) in kidney transplantation. Five-year survival results of the U.S. multicenter, randomized, comparative trial. Transplant Proc 2001; 33: 10191020.
  • 23
    Solliger HW, for the Us Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225232.
  • 24
    The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaver transplantation. Transplantation 1996; 61: 10291037.
  • 25
    European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391396.
  • 26
    Light JA, Kelly JL, Aquino A, Neu L, Denavas L, Williams K. Improving renal transplant outcomes in African Americans with OKT3 induction therapy. Transplant Proc 1993; 25: 24362438.
  • 27
    Gaston RS, Hudson SL, Deierhoi MH et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 1992; 53: 103109.
  • 28
    Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834841.
  • 29
    Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. Fk506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69: 875880.